Ultragenyx Pharmaceutical(US:RARE) Prnewswire·2026-02-11 14:06Core Viewpoint - Ultragenyx Pharmaceutical Inc is facing a federal securities class action due to allegations of making false or misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta, leading to significant stock price declines following study failures [1][2] Summary by Relevant Sections Company Overview - Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is under investigation by Faruqi & Faruqi, LLP for potential securities law violations related to its clinical trials [1] Allegations - The complaint alleges that Ultragenyx and its executives misrepresented the reliability of information regarding setrusumab's effects and downplayed risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived efficacy of the treatment [1] Stock Performance - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by more than 42% [2] Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is April 6, 2026 [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [2]